{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:22:26Z","timestamp":1790446946181,"version":"4.1.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["NSTC 114-2314-B-281 -004 \u2013"],"award-info":[{"award-number":["NSTC 114-2314-B-281 -004 \u2013"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002811","name":"Cathay General Hospital","doi-asserted-by":"publisher","award":["CGH-MR-A114017"],"award-info":[{"award-number":["CGH-MR-A114017"]}],"id":[{"id":"10.13039\/501100002811","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12012-026-10132-9","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:54:09Z","timestamp":1779548049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Doxorubicin-Induced Cardiotoxicity in Breast Cancer: Mechanistic Pathways, Pharmacogenomic Modifiers, and Translational Strategies"],"prefix":"10.1007","volume":"26","author":[{"given":"Chi-Tong","family":"Kuok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Che","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Wen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"10132_CR1","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"B Kalyanaraman","year":"2020","unstructured":"Kalyanaraman, B. (2020). Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biology, 29, 101394.","journal-title":"Redox Biology"},{"issue":"8","key":"10132_CR2","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","volume":"18","author":"BE Levis","year":"2017","unstructured":"Levis, B. E., Binkley, P. F., & Shapiro, C. L. (2017). Cardiotoxic effects of anthracycline-based therapy: What is the evidence and what are the potential harms? The Lancet Oncology, 18(8), e445\u2013e56.","journal-title":"The Lancet Oncology"},{"key":"10132_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082286","author":"S Balaji","year":"2023","unstructured":"Balaji, S., Antony, A. K., Tonchev, H., Scichilone, G., Morsy, M., Deen, H., et al. (2023). Racial disparity in anthracycline-induced cardiotoxicity in breast cancer patients. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11082286","journal-title":"Biomedicines"},{"issue":"7","key":"10132_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1139\/cjpp-2013-0470","volume":"92","author":"MF Saeed","year":"2014","unstructured":"Saeed, M. F., Premecz, S., Goyal, V., Singal, P. K., & Jassal, D. S. (2014). Catching broken hearts: Pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting. Canadian Journal of Physiology and Pharmacology, 92(7), 546\u201350.","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"issue":"11","key":"10132_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil, R., Mueller, C., Celutkiene, J., Henriksen, P. A., Lenihan, D., Dent, S., et al. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal Of Heart Failure, 22(11), 1966\u20131983.","journal-title":"European Journal Of Heart Failure"},{"issue":"6","key":"10132_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","volume":"7","author":"I Meattini","year":"2021","unstructured":"Meattini, I., Poortmans, P. M., Aznar, M. C., Becherini, C., Bonzano, E., Cardinale, D., et al. (2021). Association of breast cancer irradiation with cardiac toxic effects: A narrative review. JAMA Oncology, 7(6), 924\u201332.","journal-title":"JAMA Oncology"},{"issue":"8","key":"10132_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Jr., Sebag, I. A., et al. (2014). Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. Journal of the American College of Cardiology, 63(8), 809\u2013816.","journal-title":"Journal of the American College of Cardiology"},{"issue":"suppl 1","key":"10132_CR8","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.2024s106","volume":"70","author":"EN Silva","year":"2024","unstructured":"Silva, E. N., Ribeiro, M. L., Caldeira, L. C., Jorge, A. J. L., Rosa, M. L. G., Mesquita, E. T., et al. (2024). Biomarkers and prediction of anthracyclic cardiotoxicity in breast cancer. Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira (1992), 70(suppl 1), Article e2024S106.","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira (1992)"},{"issue":"1","key":"10132_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12944-022-01694-y","volume":"21","author":"C Abrahams","year":"2022","unstructured":"Abrahams, C., Woudberg, N. J., & Lecour, S. (2022). Anthracycline-induced cardiotoxicity: Targeting high-density lipoproteins to limit the damage? Lipids In Health And Disease, 21(1), 85.","journal-title":"Lipids In Health And Disease"},{"issue":"1","key":"10132_CR10","volume":"9","author":"JM Dos Santos","year":"2023","unstructured":"Dos Santos, J. M., Joiakim, A., Putt, D. A., Scherrer-Crosbie, M., & Kim, H. (2023). 14,15-Dihydroxyeicosatrienoic acid, a soluble epoxide hydrolase metabolite in blood, is a predictor of anthracycline-induced cardiotoxicity - A hypothesis generating study. CardioOncology, 9(1), Article 47.","journal-title":"CardioOncology"},{"key":"10132_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijcard.2021.02.013","volume":"330","author":"M Laufer-Perl","year":"2021","unstructured":"Laufer-Perl, M., Arias, O., Dorfman, S. S., Baruch, G., Rothschild, E., Beer, G., et al. (2021). Left atrial strain changes in patients with breast cancer during anthracycline therapy. International Journal Of Cardiology, 330, 238\u201344.","journal-title":"International Journal Of Cardiology"},{"issue":"1","key":"10132_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40959-022-00143-0","volume":"8","author":"DPS Sampaio","year":"2022","unstructured":"Sampaio, D. P. S., Silva, J. B. M., do Carmo Rassi, D., Freitas, A. F., Jr., & Rassi, S. (2022). Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study. Cardio-Oncology, 8(1), 17.","journal-title":"Cardio-Oncology"},{"issue":"1","key":"10132_CR13","first-page":"39","volume":"11","author":"N Poovorawan","year":"2025","unstructured":"Poovorawan, N., Susiriwatananont, T., Teerapakpinyo, C., Chariyavilaskul, P., Sitthideatphaiboon, P., Jarutasnangkul, L., et al. (2025). Long-term impact of anthracycline in early-stage breast cancer, bridging of MiRNAs profiler for early cardiotoxicity. Cardiooncology, 11(1), 39.","journal-title":"Cardiooncology"},{"issue":"1","key":"10132_CR14","volume":"7","author":"JK Lang","year":"2021","unstructured":"Lang, J. K., Karthikeyan, B., Quinones-Lombrana, A., Blair, R. H., Early, A. P., Levine, E. G., et al. (2021). CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. CardioOncology, 7(1), Article 17.","journal-title":"CardioOncology"},{"issue":"1","key":"10132_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00231-3","volume":"10","author":"HM Boen","year":"2024","unstructured":"Boen, H. M., Alaerts, M., Goovaerts, I., Saenen, J. B., Franssen, C., Vorlat, A., et al. (2024). Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: A case control study. Cardio-Oncology, 10(1), Article 26.","journal-title":"Cardio-Oncology"},{"issue":"5","key":"10132_CR16","doi-asserted-by":"publisher","first-page":"e2020168118","DOI":"10.1073\/pnas.2020168118","volume":"118","author":"KM Huang","year":"2021","unstructured":"Huang, K. M., Zavorka Thomas, M., Magdy, T., Eisenmann, E. D., Uddin, M. E., & DiGiacomo, D. F. (2021). Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences, 118(5), e2020168118.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10132_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030945","author":"JJ Osorio-Mendez","year":"2025","unstructured":"Osorio-Mendez, J. J., Gomez-Grosso, L. A., Montoya-Ortiz, G., Novoa-Herran, S., & Dominguez-Romero, Y. (2025). Small extracellular vesicles from breast cancer cells induce cardiotoxicity. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms26030945","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10132_CR18","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1007\/s10238-023-01144-8","volume":"23","author":"L Coltelli","year":"2023","unstructured":"Coltelli, L., Finale, C., Musettini, G., Fontana, A., Barletta, M. T., Lucarini, A. R., et al. (2023). Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study. Clinical and Experimental Medicine, 23(8), 5113\u20135120.","journal-title":"Clinical and Experimental Medicine"},{"issue":"1","key":"10132_CR19","first-page":"68","volume":"1","author":"AVS Macedo","year":"2019","unstructured":"Macedo, A. V. S., Hajjar, L. A., Lyon, A. R., Nascimento, B. R., Putzu, A., Rossi, L., et al. (2019). Efficacy of Dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC: CardioOncology, 1(1), 68\u201379.","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"10132_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello, V., De Laurentiis, M., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., et al. (2021). The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovascular Diabetology, 20(1), 150.","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10132_CR21","first-page":"58","volume":"10","author":"AJ Daniele","year":"2024","unstructured":"Daniele, A. J., Gregorietti, V., Costa, D., & Lopez-Fernandez, T. (2024). Use of EMPAgliflozin in the prevention of CARDiotoxicity: The EMPACARD - PILOT trial. Cardiooncology, 10(1), 58.","journal-title":"Cardiooncology"},{"issue":"4","key":"10132_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clbc.2022.01.008","volume":"22","author":"NA El-Bassiouny","year":"2022","unstructured":"El-Bassiouny, N. A., Helmy, M. W., Hassan, M. A. E., & Khedr, G. A. (2022). The cardioprotective effect of Vitamin D in breast cancer patients receiving adjuvant doxorubicin based chemotherapy. Clinical Breast Cancer, 22(4), 359\u2013366.","journal-title":"Clinical Breast Cancer"},{"issue":"1","key":"10132_CR23","first-page":"62","volume":"11","author":"JP Nesseler","year":"2025","unstructured":"Nesseler, J. P., Silos, K. D., Peony, O., Singh, A., Belen, P., Kamrava, M. R., et al. (2025). Dynamic cardiac changes in low cardiovascular risk patients with triple negative breast cancer treated with chemo-immunotherapy. Cardiooncology, 11(1), 62.","journal-title":"Cardiooncology"},{"issue":"1\u20133","key":"10132_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/ars.2021.0002","volume":"37","author":"R Tan","year":"2022","unstructured":"Tan, R., Cong, T., Xu, G., Hao, Z., Liao, J., Xie, Y., et al. (2022). Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction. Antioxidants & Redox Signaling, 37(1\u20133), 19\u201339.","journal-title":"Antioxidants & Redox Signaling"},{"issue":"1 Pt 2","key":"10132_CR25","first-page":"198","volume":"13","author":"JN Upshaw","year":"2020","unstructured":"Upshaw, J. N., Finkelman, B., Hubbard, R. A., Smith, A. M., Narayan, H. K., Arndt, L., et al. (2020). Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC: Cardiovascular Imaging, 13(1 Pt 2), 198\u2013210.","journal-title":"JACC: Cardiovascular Imaging"},{"issue":"1","key":"10132_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13046-024-03087-8","volume":"43","author":"V Del Vecchio","year":"2024","unstructured":"Del Vecchio, V., Rehman, A., Panda, S. K., Torsiello, M., Marigliano, M., Nicoletti, M. M., et al. (2024). Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance. Journal of Experimental & Clinical Cancer Research, 43(1), 166.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"8","key":"10132_CR27","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/jso.24614","volume":"115","author":"K Ning","year":"2017","unstructured":"Ning, K., Wang, T., Sun, X., Zhang, P., Chen, Y., Jin, J., et al. (2017). UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer. Journal Of Surgical Oncology, 115(8), 932\u2013940.","journal-title":"Journal Of Surgical Oncology"},{"key":"10132_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116923","volume":"237","author":"M Zhou","year":"2025","unstructured":"Zhou, M., Hong, J., Qiu, X., Xiong, Z., Liu, X., Qin, Z., et al. (2025). Serum-derived extracellular vesicles mediate acquired multidrug resistance of MCF-7 breast cancer cells induced by chemotherapeutic drugs. Biochemical Pharmacology, 237, Article 116923.","journal-title":"Biochemical Pharmacology"},{"issue":"5","key":"10132_CR29","doi-asserted-by":"publisher","first-page":"118663","DOI":"10.1016\/j.bbamcr.2020.118663","volume":"1867","author":"F Baltes","year":"2020","unstructured":"Baltes, F., Pfeifer, V., Silbermann, K., Caspers, J., von Wantoch, K., Schlesinger, M., et al. (2020). beta(1)-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1867(5), 118663.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10132_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144956","author":"F Baltes","year":"2020","unstructured":"Baltes, F., Caspers, J., Henze, S., Schlesinger, M., & Bendas, G. (2020). Targeting Discoidin Domain Receptor 1 (DDR1) signaling and its crosstalk with beta(1)-integrin emerges as a key factor for breast cancer chemosensitization upon collagen type 1 binding. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms21144956","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10132_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.21873\/cgp.20122","volume":"16","author":"E Bigagli","year":"2019","unstructured":"Bigagli, E., Cinci, L., D\u2019Ambrosio, M., & Luceri, C. (2019). Transcriptomic characterization, chemosensitivity and regulatory effects of exosomes in spontaneous EMT\/MET transitions of breast cancer cells. Cancer Genomics & Proteomics, 16(3), 163\u201373.","journal-title":"Cancer Genomics & Proteomics"},{"issue":"5","key":"10132_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.trsl.2014.10.011","volume":"165","author":"S Saha","year":"2015","unstructured":"Saha, S., Mukherjee, S., Mazumdar, M., Manna, A., Khan, P., Adhikary, A., et al. (2015). Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Translational Research, 165(5), 558\u201377.","journal-title":"Translational Research"},{"issue":"11\u201312","key":"10132_CR33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10495-022-01763-8","volume":"27","author":"H Vasiyani","year":"2022","unstructured":"Vasiyani, H., Mane, M., Rana, K., Shinde, A., Roy, M., Singh, J., et al. (2022). DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients. Apoptosis\u202f: An International Journal on Programmed Cell Death, 27(11\u201312), 961\u201378.","journal-title":"Apoptosis : An International Journal on Programmed Cell Death"},{"issue":"1\u20132","key":"10132_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijpharm.2018.03.024","volume":"542","author":"Y Chen","year":"2018","unstructured":"Chen, Y., Cheng, Y., Zhao, P., Zhang, S., Li, M., He, C., et al. (2018). Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance. International Journal Of Pharmaceutics, 542(1\u20132), 266\u2013279.","journal-title":"International Journal Of Pharmaceutics"},{"issue":"6","key":"10132_CR35","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1039\/C8BM00226F","volume":"6","author":"M Wu","year":"2018","unstructured":"Wu, M., Li, J., Lin, X., Wei, Z., Zhang, D., Zhao, B., et al. (2018). Reduction\/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery. Biomaterials Science, 6(6), 1457\u20131468.","journal-title":"Biomaterials Science"},{"issue":"sup2","key":"10132_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/21691401.2018.1453829","volume":"46","author":"R Rastegar","year":"2018","unstructured":"Rastegar, R., Akbari Javar, H., Khoobi, M., Dehghan Kelishadi, P., Hossein Yousefi, G., Doosti, M., et al. (2018). Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer. Artif Cells Nanomed Biotechnol, 46(sup2), 207\u2013216.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"4","key":"10132_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","volume":"18","author":"R Paridaens","year":"2000","unstructured":"Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., et al. (2000). Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. Journal of Clinical Oncology, 18(4), 724\u201333.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10132_CR38","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.1038\/s41598-019-54387-5","volume":"9","author":"R Li","year":"2019","unstructured":"Li, R., Tian, F., Qi, Y., Ma, L., Zhou, T., Li, Y., et al. (2019). Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). Scientific Reports, 9(1), 18135.","journal-title":"Scientific Reports"},{"key":"10132_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijbiomac.2014.02.028","volume":"66","author":"D Agudelo","year":"2014","unstructured":"Agudelo, D., Bourassa, P., Berube, G., & Tajmir-Riahi, H. A. (2014). Intercalation of antitumor drug doxorubicin and its analogue by DNA duplex: Structural features and biological implications. International Journal of Biological Macromolecules, 66, 144\u201350.","journal-title":"International Journal of Biological Macromolecules"},{"issue":"5","key":"10132_CR40","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1021\/jp411429g","volume":"118","author":"C Perez-Arnaiz","year":"2014","unstructured":"Perez-Arnaiz, C., Busto, N., Leal, J. M., & Garcia, B. (2014). New insights into the mechanism of the DNA\/doxorubicin interaction. The Journal of Physical Chemistry B, 118(5), 1288\u20131295.","journal-title":"The Journal of Physical Chemistry B"},{"issue":"3","key":"10132_CR41","doi-asserted-by":"publisher","first-page":"e22998","DOI":"10.1002\/bip.22998","volume":"107","author":"EF Silva","year":"2017","unstructured":"Silva, E. F., Bazoni, R. F., Ramos, E. B., & Rocha, M. S. (2017). DNA-doxorubicin interaction: New insights and peculiarities. Biopolymers, 107(3), e22998.","journal-title":"Biopolymers"},{"issue":"9","key":"10132_CR42","doi-asserted-by":"publisher","first-page":"e44947","DOI":"10.1371\/journal.pone.0044947","volume":"7","author":"NT Chen","year":"2012","unstructured":"Chen, N. T., Wu, C. Y., Chung, C. Y., Hwu, Y., Cheng, S. H., Mou, C. Y., et al. (2012). Probing the dynamics of doxorubicin-DNA intercalation during the initial activation of apoptosis by fluorescence lifetime imaging microscopy (FLIM). PLoS One, 7(9), e44947.","journal-title":"PLoS One"},{"issue":"1","key":"10132_CR43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1021\/ac503926g","volume":"87","author":"F Yao","year":"2015","unstructured":"Yao, F., Duan, J., Wang, Y., Zhang, Y., Guo, Y., Guo, H., et al. (2015). Nanopore single-molecule analysis of DNA-doxorubicin interactions. Analytical Chemistry, 87(1), 338\u201342.","journal-title":"Analytical Chemistry"},{"issue":"3","key":"10132_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","volume":"89","author":"RE Nicoletto","year":"2022","unstructured":"Nicoletto, R. E., & Ofner, C. M., III. (2022). Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemotherapy and Pharmacology, 89(3), 285\u2013311.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"10132_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10565-021-09640-x","volume":"39","author":"A Di Ghelli Luserna","year":"2023","unstructured":"Di Ghelli Luserna, A., Ghetti, M., Ledda, L., Ferrari, A., Bocconcelli, M., Padella, A., et al. (2023). Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. Cell Biology and Toxicology, 39(3), 795\u2013811.","journal-title":"Cell Biology and Toxicology"},{"issue":"9","key":"10132_CR46","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1007\/s11033-021-06665-7","volume":"48","author":"Y Ma","year":"2021","unstructured":"Ma, Y., North, B. J., & Shu, J. (2021). Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: Clinical implications for cancer chemotherapy. Molecular Biology Reports, 48(9), 6589\u20136601.","journal-title":"Molecular Biology Reports"},{"issue":"6","key":"10132_CR47","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1021\/acschembio.3c00033","volume":"18","author":"M Bellamri","year":"2023","unstructured":"Bellamri, M., Terrell, J. T., Brandt, K., Gruppi, F., Turesky, R. J., & Rizzo, C. J. (2023). Anthracyclines react with apurinic\/apyrimidinic sites in DNA. Acs Chemical Biology, 18(6), 1315\u20131323.","journal-title":"Acs Chemical Biology"},{"key":"10132_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119527","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan, S., & Sivalingam, N. (2021). A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences, 278, Article 119527.","journal-title":"Life Sciences"},{"issue":"3","key":"10132_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1039\/C9TB02266J","volume":"8","author":"J Yan","year":"2020","unstructured":"Yan, J., Chen, J., Zhang, N., Yang, Y., Zhu, W., Li, L., et al. (2020). Mitochondria-targeted tetrahedral DNA nanostructures for doxorubicin delivery and enhancement of apoptosis. Journal of Materials Chemistry. B, 8(3), 492\u2013503.","journal-title":"Journal of Materials Chemistry. B"},{"issue":"22","key":"10132_CR50","doi-asserted-by":"publisher","first-page":"12698","DOI":"10.1021\/acsomega.9b04369","volume":"5","author":"A Altharawi","year":"2020","unstructured":"Altharawi, A., Rahman, K. M., & Chan, K. L. A. (2020). Identifying the responses from the Estrogen Receptor-expressed MCF7 cells treated in anticancer drugs of different modes of action using live-cell FTIR spectroscopy. ACS Omega, 5(22), 12698\u201312706.","journal-title":"ACS Omega"},{"issue":"7","key":"10132_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11912-018-0696-8","volume":"20","author":"VY Chang","year":"2018","unstructured":"Chang, V. Y., & Wang, J. J. (2018). Pharmacogenetics of chemotherapy-induced cardiotoxicity. Current Oncology Reports, 20(7), 52.","journal-title":"Current Oncology Reports"},{"issue":"3","key":"10132_CR52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/pgs.15.162","volume":"17","author":"DL Hertz","year":"2016","unstructured":"Hertz, D. L., Caram, M. V., Kidwell, K. M., Thibert, J. N., Gersch, C., Seewald, N. J., et al. (2016). Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics, 17(3), 231\u201340.","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10132_CR53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","volume":"27","author":"DJ Serie","year":"2017","unstructured":"Serie, D. J., Crook, J. E., Necela, B. M., Dockter, T. J., Wang, X., Asmann, Y. W., et al. (2017). Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenetics and Genomics, 27(10), 378\u201385.","journal-title":"Pharmacogenetics and Genomics"},{"issue":"3","key":"10132_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/tpj.2013.32","volume":"14","author":"S Yao","year":"2014","unstructured":"Yao, S., Sucheston, L. E., Zhao, H., Barlow, W. E., Zirpoli, G., Liu, S., et al. (2014). Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. The Pharmacogenomics Journal, 14(3), 241\u2013247.","journal-title":"The Pharmacogenomics Journal"},{"key":"10132_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040539","author":"EK Abdelfattah","year":"2025","unstructured":"Abdelfattah, E. K., Hosny, S. M., Kassem, A. B., Moustafa, H. A. M., Tawfeik, A. M., Abdelhafez, M. N., et al. (2025). Pharmacogenetics as a future tool to risk-stratify breast cancer patients according to chemotoxicity potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) regimen. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph18040539","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10132_CR56","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00280-021-04244-y","volume":"87","author":"E Turijan-Espinoza","year":"2021","unstructured":"Turijan-Espinoza, E., Ruiz-Rodriguez, V. M., Uresti-Rivera, E. E., Martinez-Leija, E., Zermeno-Nava, J. J., Guel-Panola, A., et al. (2021). Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients. Cancer Chemotherapy And Pharmacology, 87(6), 843\u2013853.","journal-title":"Cancer Chemotherapy And Pharmacology"},{"issue":"3","key":"10132_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3816\/CBC.2009.n.026","volume":"9","author":"J George","year":"2009","unstructured":"George, J., Dharanipragada, K., Krishnamachari, S., Chandrasekaran, A., Sam, S. S., & Sunder, E. (2009). A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clinical Breast Cancer, 9(3), 161\u2013165.","journal-title":"Clinical Breast Cancer"},{"issue":"4","key":"10132_CR58","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","volume":"145","author":"T Magdy","year":"2022","unstructured":"Magdy, T., Jouni, M., Kuo, H. H., Weddle, C. J., Lyra-Leite, D., Fonoudi, H., et al. (2022). Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation, 145(4), 279\u2013294.","journal-title":"Circulation"},{"issue":"9","key":"10132_CR59","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., et al. (2015). A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics, 47(9), 1079\u20131084.","journal-title":"Nature Genetics"},{"issue":"12","key":"10132_CR60","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","volume":"28","author":"T Magdy","year":"2021","unstructured":"Magdy, T., Jiang, Z., Jouni, M., Fonoudi, H., Lyra-Leite, D., Jung, G., et al. (2021). RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell, 28(12), 2076\u20132089. e7.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10132_CR61","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.stemcr.2022.03.002","volume":"17","author":"H Huang","year":"2022","unstructured":"Huang, H., Christidi, E., Shafaattalab, S., Davis, M. K., Tibbits, G. F., & Brunham, L. R. (2022). RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Reports, 17(4), 756\u2013765.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"10132_CR62","doi-asserted-by":"publisher","first-page":"9698","DOI":"10.1038\/s41598-017-09517-2","volume":"7","author":"MAT Hildebrandt","year":"2017","unstructured":"Hildebrandt, M. A. T., Reyes, M., Wu, X., Pu, X., Thompson, K. A., Ma, J., et al. (2017). Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors. Scientific Reports, 7(1), 9698.","journal-title":"Scientific Reports"},{"issue":"7","key":"10132_CR63","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/FPC.0000000000000284","volume":"27","author":"QS Wells","year":"2017","unstructured":"Wells, Q. S., Veatch, O. J., Fessel, J. P., Joon, A. Y., Levinson, R. T., Mosley, J. D., et al. (2017). Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenetics and Genomics, 27(7), 247\u201354.","journal-title":"Pharmacogenetics and Genomics"},{"issue":"1","key":"10132_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41525-021-00199-4","volume":"6","author":"EN Scott","year":"2021","unstructured":"Scott, E. N., Wright, G. E. B., Drogemoller, B. I., Hasbullah, J. S., Gunaretnam, E. P., Miao, F., et al. (2021). Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity. NPJ Genomic Medicine, 6(1), 35.","journal-title":"NPJ Genomic Medicine"},{"issue":"1","key":"10132_CR65","first-page":"38","volume":"6","author":"H Fonoudi","year":"2024","unstructured":"Fonoudi, H., Jouni, M., Cejas, R. B., Magdy, T., Blancard, M., Ge, N., et al. (2024). Functional validation of Doxorubicin-induced cardiotoxicity-related genes. JACC: CardioOncology, 6(1), 38\u201350.","journal-title":"JACC: CardioOncology"},{"key":"10132_CR66","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.33480","author":"DA Knowles","year":"2018","unstructured":"Knowles, D. A., Burrows, C. K., Blischak, J. D., Patterson, K. M., Serie, D. J., Norton, N., et al. (2018). Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes. Elife. https:\/\/doi.org\/10.7554\/eLife.33480","journal-title":"Elife"},{"key":"10132_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184079","author":"N Norton","year":"2021","unstructured":"Norton, N., Weil, R. M., & Advani, P. P. (2021). Inter-individual variation and cardioprotection in anthracycline-induced heart failure. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm10184079","journal-title":"Journal of Clinical Medicine"},{"key":"10132_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/biom15070971","author":"R Yucer","year":"2025","unstructured":"Yucer, R., Piccinno, R., Ooko, E., Dawood, M., Bringmann, G., & Efferth, T. (2025). Predictive and prognostic relevance of ABC transporters for resistance to anthracycline derivatives. Biomolecules. https:\/\/doi.org\/10.3390\/biom15070971","journal-title":"Biomolecules"},{"key":"10132_CR69","doi-asserted-by":"publisher","first-page":"111864","DOI":"10.1016\/j.cellsig.2025.111864","volume":"132","author":"S Sahoo","year":"2025","unstructured":"Sahoo, S., Kumari, S., Neeli, P. K., Pulipaka, S., Kuncha, M., Chandra, Y., et al. (2025). MTDH\u22067-mediated mTOR activation drives doxorubicin resistance in triple-negative breast cancer: Relevance of mTORC1 inhibition on chemosensitization. Cellular Signalling, 132, 111864.","journal-title":"Cellular Signalling"},{"issue":"1","key":"10132_CR70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11033-022-08028-2","volume":"50","author":"S Shivhare","year":"2023","unstructured":"Shivhare, S., & Das, A. (2023). Cell density modulates chemoresistance in breast cancer cells through differential expression of ABC transporters. Molecular Biology Reports, 50(1), 215\u2013225.","journal-title":"Molecular Biology Reports"},{"key":"10132_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10060949","author":"M Jadhao","year":"2021","unstructured":"Jadhao, M., Tsai, E. M., Yang, H. C., Chen, Y. F., Liang, S. S., Wang, T. N., et al. (2021). The long-term DEHP exposure confers multidrug resistance of triple-negative breast cancer cells through ABC transporters and intracellular ROS. Antioxidants. https:\/\/doi.org\/10.3390\/antiox10060949","journal-title":"Antioxidants"},{"key":"10132_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098136","author":"EM Packeiser","year":"2023","unstructured":"Packeiser, E. M., Engels, L., Nolte, I., Goericke-Pesch, S., & Murua Escobar, H. (2023). MDR1 inhibition reverses Doxorubicin-resistance in six Doxorubicin-resistant canine prostate and bladder cancer cell lines. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms24098136","journal-title":"International Journal of Molecular Sciences"},{"key":"10132_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111582","author":"S Paskas","year":"2023","unstructured":"Paskas, S., Stockmann, P., Mijatovic, S., Kuhnert, L., Honscha, W., Hey-Hawkins, E., et al. (2023). Carborane-based ABCG2-inhibitors sensitize ABC-(over)expressing cancer cell lines for Doxorubicin and Cisplatin. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph16111582","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10132_CR74","doi-asserted-by":"publisher","first-page":"105975","DOI":"10.1016\/j.phrs.2021.105975","volume":"175","author":"GEF Abd-Ellatef","year":"2022","unstructured":"Abd-Ellatef, G. E. F., Gazzano, E., El-Desoky, A. H., Hamed, A. R., Kopecka, J., Belisario, D. C., et al. (2022). Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. Pharmacological Research, 175, 105975.","journal-title":"Pharmacological Research"},{"issue":"2","key":"10132_CR75","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","volume":"27","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei, S., Gholami, M. H., Hashemi, F., Zabolian, A., Farahani, M. V., Hushmandi, K., et al. (2022). Advances in understanding the role of P-gp in Doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discovery Today, 27(2), 436\u201355.","journal-title":"Drug Discovery Today"},{"key":"10132_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1486783","volume":"15","author":"XY Lu","year":"2024","unstructured":"Lu, X. Y., & Jin, H. (2024). MiRNAs function in the development of resistance against doxorubicin in cancer cells: Targeting ABC transporters. Frontiers in Pharmacology, 15, Article 1486783.","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10132_CR77","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/17425255.2021.1887139","volume":"17","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Wang, Y., Qin, Z., Cai, S., Yu, L., Hu, H., et al. (2021). The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opinion on Drug Metabolism & Toxicology, 17(3), 291\u2013306.","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"3","key":"10132_CR78","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1186\/bcr3666","volume":"16","author":"A Faversani","year":"2014","unstructured":"Faversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D. C., et al. (2014). Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Research, 16(3), R55.","journal-title":"Breast Cancer Research"},{"issue":"10","key":"10132_CR79","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.4161\/cbt.29693","volume":"15","author":"E Tarasewicz","year":"2014","unstructured":"Tarasewicz, E., Hamdan, R., Straehla, J., Hardy, A., Nunez, O., Zelivianski, S., et al. (2014). CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin. Cancer Biology & Therapy, 15(10), 1301\u201311.","journal-title":"Cancer Biology & Therapy"},{"key":"10132_CR80","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbi.2015.03.017","volume":"235","author":"S Wang","year":"2015","unstructured":"Wang, S., Wang, L., Chen, M., & Wang, Y. (2015). Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Chemical-Biological Interactions, 235, 76\u201384.","journal-title":"Chemical-Biological Interactions"},{"issue":"1","key":"10132_CR81","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1124\/jpet.118.249151","volume":"366","author":"W Wang","year":"2018","unstructured":"Wang, W., Zhang, B., Mani, A. M., Wu, Z., Fan, Y., Li, W., et al. (2018). Survivin inhibitors mitigate chemotherapeutic resistance in breast cancer cells by suppressing genotoxic nuclear factor-kappaB activation. Journal of Pharmacology And Experimental Therapeutics, 366(1), 184\u2013193.","journal-title":"Journal of Pharmacology And Experimental Therapeutics"},{"issue":"3","key":"10132_CR82","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/acsbiomaterials.0c01511","volume":"7","author":"P Norouzi","year":"2021","unstructured":"Norouzi, P., Motasadizadeh, H., Atyabi, F., Dinarvand, R., Gholami, M., Farokhi, M., et al. (2021). Combination therapy of breast cancer by codelivery of doxorubicin and survivin siRNA using polyethylenimine modified silk fibroin nanoparticles. ACS Biomaterials Science & Engineering, 7(3), 1074\u20131087.","journal-title":"ACS Biomaterials Science & Engineering"},{"key":"10132_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112537","author":"S Eljack","year":"2022","unstructured":"Eljack, S., Allard-Vannier, E., Misericordia, Y., Herve-Aubert, K., Aubrey, N., Chourpa, I., et al. (2022). Combination of nanovectorized siRNA directed against Survivin with Doxorubicin for efficient anti-cancer activity in HER2\u2009+\u2009breast cancer cells. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14112537","journal-title":"Pharmaceutics"},{"issue":"22","key":"10132_CR84","doi-asserted-by":"publisher","first-page":"35804","DOI":"10.18632\/oncotarget.16208","volume":"8","author":"K Nam","year":"2017","unstructured":"Nam, K., Son, S. H., Oh, S., Jeon, D., Kim, H., & Noh, D. Y. (2017). Binding of galectin-1 to integrin beta1 potentiates drug resistance by promoting survivin expression in breast cancer cells. Oncotarget, 8(22), 35804\u201323.","journal-title":"Oncotarget"},{"issue":"4","key":"10132_CR85","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41416-022-02077-x","volume":"128","author":"S Zhao","year":"2023","unstructured":"Zhao, S., Pan, T., Deng, J., Cao, L., Vicencio, J. M., Liu, J., et al. (2023). Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. British Journal Of Cancer, 128(4), 665\u2013677.","journal-title":"British Journal Of Cancer"},{"issue":"1","key":"10132_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01901-1","volume":"40","author":"Q Yang","year":"2021","unstructured":"Yang, Q., Zhao, S., Shi, Z., Cao, L., Liu, J., Pan, T., et al. (2021). Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2\/STAT3 signaling. Journal of Experimental & Clinical Cancer Research, 40(1), Article 120.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"2","key":"10132_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-015-3372-9","volume":"151","author":"Y Hu","year":"2015","unstructured":"Hu, Y., Xu, K., & Yague, E. (2015). miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Research and Treatment, 151(2), 269\u2013280.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10132_CR88","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1038\/s41598-019-41472-y","volume":"9","author":"E Tormo","year":"2019","unstructured":"Tormo, E., Ballester, S., Adam-Artigues, A., Burgues, O., Alonso, E., Bermejo, B., et al. (2019). The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Scientific Reports, 9(1), 5316.","journal-title":"Scientific Reports"},{"issue":"10","key":"10132_CR89","first-page":"1193","volume":"38","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Wang, C., Huang, C., Yang, J., & Wang, J. (2023). Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression. Histology and Histopathology, 38(10), 1193\u20131204.","journal-title":"Histology and Histopathology"},{"issue":"2","key":"10132_CR90","doi-asserted-by":"publisher","first-page":"9885","DOI":"10.1080\/21655979.2021.1999373","volume":"12","author":"R Ren","year":"2021","unstructured":"Ren, R., Yuan, Z., & Xu, Z. (2021). miRNA-144 targeting DNAJC3-AS1 reverses the resistance of the breast cancer cell line Michigan Cancer Foundation-7 to doxorubicin. Bioengineered, 12(2), 9885\u20139892.","journal-title":"Bioengineered"},{"issue":"8","key":"10132_CR91","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/jpp\/rgaa031","volume":"73","author":"K Jamialahmadi","year":"2021","unstructured":"Jamialahmadi, K., Zahedipour, F., & Karimi, G. (2021). The role of microRNAs on doxorubicin drug resistance in breast cancer. Journal of Pharmacy and Pharmacology, 73(8), 997\u20131006.","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"5","key":"10132_CR92","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s10142-024-01431-x","volume":"24","author":"FE Meinag","year":"2024","unstructured":"Meinag, F. E., Fatahi, M., Vahedian, V., Maroufi, N. F., Mosayyebi, B., Ahmadi, E., et al. (2024). Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view. Functional and Integrative Genomics, 24(5), 150.","journal-title":"Functional and Integrative Genomics"},{"issue":"1","key":"10132_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01345-w","volume":"15","author":"X Wang","year":"2022","unstructured":"Wang, X., Chen, T., Li, C., Li, W., Zhou, X., Li, Y., et al. (2022). CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. Journal of Hematology & Oncology, 15(1), Article 122.","journal-title":"Journal of Hematology & Oncology"},{"issue":"4","key":"10132_CR94","doi-asserted-by":"publisher","first-page":"157","DOI":"10.32604\/or.2022.027547","volume":"30","author":"S Misir","year":"2022","unstructured":"Misir, S., Yaman, S. O., Petrovic, N., Sumer, C., Hepokur, C., & Aliyazicioglu, Y. (2022). circRNAs in drug resistance of breast cancer. Oncology Research, 30(4), 157\u2013172.","journal-title":"Oncology Research"},{"key":"10132_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1511029","volume":"16","author":"M Diab","year":"2025","unstructured":"Diab, M., Hamdi, A., Al-Obeidat, F., Hafez, W., Cherrez-Ojeda, I., Gador, M., et al. (2025). Discovery of drug transporter inhibitors tied to long noncoding RNA in resistant cancer cells; a computational model -in silico- study. Frontiers in Immunology, 16, Article 1511029.","journal-title":"Frontiers in Immunology"},{"key":"10132_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104516","volume":"204","author":"A Ahmadi-Hadad","year":"2024","unstructured":"Ahmadi-Hadad, A., de Queiroz, P. C. C., Schettini, F., & Giuliano, M. (2024). Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200\/205: A systematic review. Critical Reviews in Oncology\/Hematology, 204, Article 104516.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10132_CR97","first-page":"801","volume":"15","author":"HK Chen","year":"2023","unstructured":"Chen, H. K., Chen, Y. L., Wang, C. Y., Chung, W. P., Fang, J. H., Lai, M. D., et al. (2023). ABCB1 regulates immune genes in breast cancer. Breast Cancer (Dove Med Press), 15, 801\u2013811.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10132_CR98","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000437","author":"L Blukacz","year":"2024","unstructured":"Blukacz, L., Nuciforo, S., Fucile, G., Trulsson, F., Duthaler, U., Wieland, S., et al. (2024). Inhibition of the transmembrane transporter ABCB1 overcomes resistance to Doxorubicin in patient-derived organoid models of HCC. Hepatology Communications. https:\/\/doi.org\/10.1097\/HC9.0000000000000437","journal-title":"Hepatology Communications"},{"issue":"9","key":"10132_CR99","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12032-024-02468-5","volume":"41","author":"MC Karthikeyan","year":"2024","unstructured":"Karthikeyan, M. C., Srinivasan, C., Prabhakar, K., Manogar, P., Jayaprakash, A., & Arockiam, A. J. V. (2024). Doxorubicin downregulates cell cycle regulatory hub genes in breast cancer cells. Medical Oncology, 41(9), 220.","journal-title":"Medical Oncology"},{"key":"10132_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.708066","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang, X., Yan, J., Shen, B., & Wei, G. (2021). Integrated chromatin accessibility and transcriptome landscapes of doxorubicin-resistant breast cancer cells. Frontiers in Cell and Developmental Biology, 9, Article 708066.","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10132_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","author":"NS van den Ende","year":"2023","unstructured":"van den Ende, N. S., Nguyen, A. H., Jager, A., Kok, M., Debets, R., & van Deurzen, C. H. M. (2023). Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: A systematic review. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms24032969","journal-title":"International Journal of Molecular Sciences"},{"key":"10132_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103035","volume":"70","author":"M Shen","year":"2024","unstructured":"Shen, M., Cao, S., Long, X., Xiao, L., Yang, L., Zhang, P., et al. (2024). DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biology, 70, Article 103035.","journal-title":"Redox Biology"},{"key":"10132_CR103","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.drup.2023.100974","volume":"69","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z., Shen, H., Xu, J., Fang, Z., Wo, G., Ma, Y., et al. (2023). GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 69, 100974.","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"3","key":"10132_CR104","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/1535370217746383","volume":"243","author":"LR Yu","year":"2018","unstructured":"Yu, L. R., Cao, Z., Makhoul, I., Daniels, J. R., Klimberg, S., Wei, J. Y., et al. (2018). Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Experimental Biology and Medicine, 243(3), 248\u2013255.","journal-title":"Experimental Biology and Medicine"},{"issue":"5","key":"10132_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100798","volume":"66","author":"S Mohammed","year":"2025","unstructured":"Mohammed, S., Kalogeropoulos, A. P., Alvarado, V., Weisfelner-Bloom, M., & Clarke, C. J. (2025). Serum and plasma sphingolipids as biomarkers of chemotherapy-induced cardiotoxicity in female patients with breast cancer. Journal of Lipid Research, 66(5), Article 100798.","journal-title":"Journal of Lipid Research"},{"issue":"7","key":"10132_CR106","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamacardio.2023.1229","volume":"8","author":"AF Yu","year":"2023","unstructured":"Yu, A. F., Moore, Z. R., Moskowitz, C. S., Liu, J. E., Dang, C. T., Ramanathan, L., et al. (2023). Association of circulating cardiomyocyte cell-free DNA with cancer therapy-related cardiac dysfunction in patients undergoing treatment for ERBB2-positive breast cancer. JAMA Cardiology, 8(7), 697\u2013702.","journal-title":"JAMA Cardiology"},{"issue":"9\u201310","key":"10132_CR107","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12012-023-09806-5","volume":"23","author":"D Xiong","year":"2023","unstructured":"Xiong, D., Yang, J., Li, D., & Wang, J. (2023). Exploration of key immune-related transcriptomes associated with Doxorubicin-induced cardiotoxicity in patients with breast cancer. Cardiovascular Toxicology, 23(9\u201310), 329\u2013348.","journal-title":"Cardiovascular Toxicology"},{"key":"10132_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179735","author":"VK Todorova","year":"2024","unstructured":"Todorova, V. K., Azhar, G., Stone, A., Malapati, S. J., Che, Y., Zhang, W., et al. (2024). Neutrophil biomarkers can predict cardiotoxicity of Anthracyclines in breast cancer. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25179735","journal-title":"International Journal of Molecular Sciences"},{"key":"10132_CR109","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.freeradbiomed.2025.06.049","volume":"238","author":"HY Lin","year":"2025","unstructured":"Lin, H. Y., Wang, W. K., Lin, C. H., Kuei, C. H., Lee, H. H., & Lin, K. Y. (2025). The IL-8\/NF-kappaB feedback loop confers a Paclitaxel-sensitive\/Doxorubicin-resistant phenotype in triple-negative breast cancer. Free Radical Biology & Medicine, 238, 316\u201328.","journal-title":"Free Radical Biology & Medicine"},{"issue":"3","key":"10132_CR110","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-020-05836-7","volume":"183","author":"WS Al Amri","year":"2020","unstructured":"Al Amri, W. S., Baxter, D. E., Hanby, A. M., Stead, L. F., Verghese, E. T., Thorne, J. L., et al. (2020). Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants. Breast Cancer Research and Treatment, 183(3), 607\u201316.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"6","key":"10132_CR111","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtha.2024.02.008","volume":"22","author":"SM Lind","year":"2024","unstructured":"Lind, S. M., Sletten, M., Hellenes, M., Mathelier, A., Tekpli, X., Tinholt, M., et al. (2024). Coagulation factor V in breast cancer: A p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy. Journal of Thrombosis and Haemostasis, 22(6), 1569\u20131582.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10132_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810901","author":"R Vishnubalaji","year":"2022","unstructured":"Vishnubalaji, R., Abdel-Razeq, H., Gehani, S., Albagha, O. M. E., & Alajez, N. M. (2022). Identification of a gene panel predictive of triple-negative breast cancer response to neoadjuvant chemotherapy employing transcriptomic and functional validation. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms231810901","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"10132_CR113","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-21-3215","volume":"28","author":"KRM Blenman","year":"2022","unstructured":"Blenman, K. R. M., Marczyk, M., Karn, T., Qing, T., Li, X., Gunasekharan, V., et al. (2022). Predictive markers of response to neoadjuvant Durvalumab with Nab-Paclitaxel and dose-dense Doxorubicin\/Cyclophosphamide in basal-like triple-negative breast cancer. Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research, 28(12), 2587\u201397.","journal-title":"Clinical Cancer Research : An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10132_CR114","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-024-02019-6","volume":"23","author":"Y Li","year":"2024","unstructured":"Li, Y., Wang, Z., Yang, J., Sun, Y., He, Y., Wang, Y., et al. (2024). CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K\/AKT\/mTOR activation. Molecular Cancer, 23(1), 102.","journal-title":"Molecular Cancer"},{"issue":"Pt B","key":"10132_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113191","volume":"142","author":"P Gu","year":"2024","unstructured":"Gu, P., Ding, W., Zhu, W., Shen, L., Zhang, L., Wang, W., et al. (2024). MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK\/c-Jun and p38 MAPK signaling pathway activation. International Immunopharmacology, 142(Pt B), Article 113191.","journal-title":"International Immunopharmacology"},{"issue":"1","key":"10132_CR116","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41420-024-02196-9","volume":"10","author":"H Zhu","year":"2024","unstructured":"Zhu, H., Jiang, C. W., Zhang, W. L., Yang, Z. Y., & Sun, G. (2024). Targeting oncogenic MAGEA6 sensitizes triple negative breast cancer to doxorubicin through its autophagy and ferroptosis by stabling AMPKalpha1. Cell Death Discovery, 10(1), 430.","journal-title":"Cell Death Discovery"},{"issue":"3","key":"10132_CR117","doi-asserted-by":"publisher","first-page":"949","DOI":"10.31557\/APJCP.2025.26.3.949","volume":"26","author":"R Parial","year":"2025","unstructured":"Parial, R., Islam, S., Ahmed, R., Jerin, N., Alam, S. M. S., Rahman, M. M., et al. (2025). Increased expression of PTCH1 and GLI1 in Bangladeshi TNBC patients after treatment with doxorubicin and cyclophosphamide suggests a favorable response to chemotherapy. Asian Pacific Journal of Cancer Prevention, 26(3), 949\u2013958.","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"1","key":"10132_CR118","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12967-025-06246-3","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang, K., Guo, L., Li, X., Hu, Y., & Luo, N. (2025). Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis. Journal of Translational Medicine, 23(1), 247.","journal-title":"Journal of Translational Medicine"},{"issue":"23","key":"10132_CR119","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41388-024-03030-3","volume":"43","author":"X Chen","year":"2024","unstructured":"Chen, X., Ma, C., Li, Y., Liang, Y., Chen, T., Han, D., et al. (2024). COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk. Oncogene, 43(23), 1742\u201356.","journal-title":"Oncogene"},{"issue":"9","key":"10132_CR120","volume":"9","author":"EC de Baat","year":"2022","unstructured":"de Baat, E. C., Mulder, R. L., Armenian, S., Feijen, E. A., Grotenhuis, H., Hudson, M. M., et al. (2022). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database of Systematic Reviews, 9(9), Article CD014638.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10132_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239141","volume":"14","author":"H Mody","year":"2023","unstructured":"Mody, H., Vaidya, T. R., Lezeau, J., Taha, K., & Ait-Oudhia, S. (2023). In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: A mechanism-based pharmacokinetic\/pharmacodynamic modeling approach. Frontiers in Pharmacology, 14, Article 1239141.","journal-title":"Frontiers in Pharmacology"},{"key":"10132_CR122","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers13174421","volume":"13","author":"F Schettini","year":"2021","unstructured":"Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., Onesti, C. E., et al. (2021). Anthracyclines strike back: Rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel), 13, 17.","journal-title":"Cancers (Basel)"},{"key":"10132_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.746114","volume":"12","author":"W Hu","year":"2021","unstructured":"Hu, W., Lv, K., Teng, R., Chen, J., Xu, C., Jin, L., et al. (2021). Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I-III breast cancer. Frontiers in Genetics, 12, Article 746114.","journal-title":"Frontiers in Genetics"},{"issue":"15","key":"10132_CR124","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1039\/D4BM00478G","volume":"12","author":"D Paolino","year":"2024","unstructured":"Paolino, D., d\u2019Avanzo, N., Canato, E., Ciriolo, L., Grigoletto, A., Cristiano, M. C., et al. (2024). Improved anti-breast cancer activity by doxorubicin-loaded super stealth liposomes. Biomaterials Science, 12(15), 3933\u20133946.","journal-title":"Biomaterials Science"},{"issue":"5","key":"10132_CR125","first-page":"807","volume":"12","author":"M Li","year":"2023","unstructured":"Li, M., Wang, L., & Du, J. (2023). Clinical observation of liposomal doxorubicin on liver and renal function in patients with breast cancer. Toxicology Research (Cambridge, England), 12(5), 807\u201313.","journal-title":"Toxicology Research (Cambridge, England)"},{"key":"10132_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.827446","volume":"13","author":"W Zhuang","year":"2022","unstructured":"Zhuang, W., Lai, X., Mai, Q., Ye, S., Chen, J., Liu, Y., et al. (2022). Biomarkers of PEGylated liposomal doxorubicin-induced hypersensitivity reaction in breast cancer patients based on metabolomics. Frontiers in Pharmacology, 13, Article 827446.","journal-title":"Frontiers in Pharmacology"},{"key":"10132_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176803","volume":"978","author":"Y Naeimzadeh","year":"2024","unstructured":"Naeimzadeh, Y., Tajbakhsh, A., Nemati, M., & Fallahi, J. (2024). Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. European Journal of Pharmacology, 978, Article 176803.","journal-title":"European Journal of Pharmacology"},{"key":"10132_CR128","doi-asserted-by":"publisher","DOI":"10.2174\/0115680266371287250402051235","author":"RP Bhole","year":"2025","unstructured":"Bhole, R. P., Maldhure, G. S., Kapare, H. S., Labhade, S. D., & Gurav, S. S. (2025). Exploring SGLT2 inhibitors\u2019 activity in breast cancer: An overview. Current Topics in Medicinal Chemistry. https:\/\/doi.org\/10.2174\/0115680266371287250402051235","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"1","key":"10132_CR129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","volume":"15","author":"A Bisht","year":"2025","unstructured":"Bisht, A., Avinash, D., Sahu, K. K., Patel, P., Das Gupta, G., & Kurmi, B. D. (2025). A comprehensive review on doxorubicin: Mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research, 15(1), 102\u2013133.","journal-title":"Drug Delivery and Translational Research"},{"issue":"6","key":"10132_CR130","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1021\/acsnano.2c03573","volume":"16","author":"L Yang","year":"2022","unstructured":"Yang, L., Zhang, Y., Zhang, Y., Xu, Y., Li, Y., Xie, Z., et al. (2022). Live macrophage-delivered doxorubicin-loaded liposomes effectively treat triple-negative breast cancer. ACS Nano, 16(6), 9799\u2013809.","journal-title":"ACS Nano"},{"issue":"1","key":"10132_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02518-0","volume":"22","author":"R Sarkar","year":"2024","unstructured":"Sarkar, R., Biswas, S., Ghosh, R., Samanta, P., Pakhira, S., Mondal, M., et al. (2024). Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3\u2019-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer. Journal of Nanobiotechnology, 22(1), Article 285.","journal-title":"Journal of Nanobiotechnology"},{"issue":"9","key":"10132_CR132","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.18632\/aging.103138","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Chen, W., Bai, J., Jin, L., Kang, X., Zhang, H., et al. (2020). Pluronic P123 modified nano micelles loaded with doxorubicin enhanced tumor-suppressing effect on drug-resistant breast cancer cells. Aging (Albany NY), 12(9), 8289\u20138300.","journal-title":"Aging (Albany NY)"},{"issue":"25","key":"10132_CR133","doi-asserted-by":"publisher","first-page":"23315","DOI":"10.1021\/acsnano.5c06302","volume":"19","author":"T Hao","year":"2025","unstructured":"Hao, T., Guo, H., Wang, C., Jing, S., Zhang, W., Zeng, Y., et al. (2025). Mitochondria-targeted microneedles reverse doxorubicin resistance via apoptosis-ferroptosis synergy. Acs Nano, 19(25), 23315\u201323333.","journal-title":"Acs Nano"},{"key":"10132_CR134","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","volume":"348","author":"M Kim","year":"2022","unstructured":"Kim, M., Lee, J. S., Kim, W., Lee, J. H., Jun, B. H., Kim, K. S., et al. (2022). Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. Journal of Controlled Release: Official Journal of the Controlled Release Society, 348, 893\u2013910.","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"issue":"9","key":"10132_CR135","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kummel, S., Bergh, J., et al. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810\u2013821.","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10132_CR136","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41388-024-02972-y","volume":"43","author":"L Yang","year":"2024","unstructured":"Yang, L., Wang, M., Wang, Y., Zhu, Y., Wang, J., Wu, M., et al. (2024). LINC00460-FUS-MYC feedback loop drives breast cancer metastasis and doxorubicin resistance. Oncogene, 43(17), 1249\u20131262.","journal-title":"Oncogene"},{"issue":"1","key":"10132_CR137","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13045-021-01194-z","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu, S., Sun, Y., Hou, Y., Yang, L., Wan, X., Qin, Y., et al. (2021). A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. Journal of Hematology & Oncology, 14(1), 178.","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10132_CR138","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1038\/s41467-022-34917-y","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu, X., Shen, F., Jiang, G., Xue, G., Philips, S., Gardner, L., et al. (2022). A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes. Nature Communications, 13(1), 7171.","journal-title":"Nature Communications"},{"issue":"20","key":"10132_CR139","doi-asserted-by":"publisher","first-page":"e38714","DOI":"10.1016\/j.heliyon.2024.e38714","volume":"10","author":"J Jang","year":"2024","unstructured":"Jang, J., Jung, H., Jeong, J., Jeon, J., Lee, K., Jang, H. R., et al. (2024). Modeling doxorubicin-induced-cardiotoxicity through breast cancer patient specific iPSC-derived heart organoid. Heliyon, 10(20), e38714.","journal-title":"Heliyon"},{"issue":"15","key":"10132_CR140","doi-asserted-by":"publisher","first-page":"e2004258","DOI":"10.1002\/smll.202004258","volume":"17","author":"J Lee","year":"2021","unstructured":"Lee, J., Mehrotra, S., Zare-Eelanjegh, E., Rodrigues, R. O., Akbarinejad, A., Ge, D., et al. (2021). A heart-breast cancer-on-a-chip platform for disease modeling and monitoring of cardiotoxicity induced by cancer chemotherapy. Small (Weinheim An Der Bergstrasse, Germany), 17(15), e2004258.","journal-title":"Small (Weinheim An Der Bergstrasse, Germany)"},{"issue":"46","key":"10132_CR141","doi-asserted-by":"publisher","first-page":"18384","DOI":"10.1021\/acs.analchem.4c02691","volume":"96","author":"T Fang","year":"2024","unstructured":"Fang, T., Xie, X., Lu, W., Hong, Z., Peng, W., Zhou, J., et al. (2024). Patient-derived organoids on a microarray for drug resistance study in breast cancer. Analytical Chemistry, 96(46), 18384\u201318391.","journal-title":"Analytical Chemistry"},{"issue":"8","key":"10132_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105021","volume":"299","author":"JM Hogstrom","year":"2023","unstructured":"Hogstrom, J. M., Cruz, K. A., Selfors, L. M., Ward, M. N., Mehta, T. S., Kanarek, N., et al. (2023). Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms. The Journal of Biological Chemistry, 299(8), Article 105021.","journal-title":"The Journal of Biological Chemistry"},{"key":"10132_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010261","author":"N Bock","year":"2023","unstructured":"Bock, N., Forouz, F., Hipwood, L., Clegg, J., Jeffery, P., Gough, M., et al. (2023). GelMA, click-chemistry gelatin and bioprinted polyethylene glycol-based hydrogels as 3D ex vivo drug testing platforms for patient-derived breast cancer organoids. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15010261","journal-title":"Pharmaceutics"},{"issue":"24","key":"10132_CR144","volume":"9","author":"AZ Ogunleye","year":"2022","unstructured":"Ogunleye, A. Z., Piyawajanusorn, C., Goncalves, A., Ghislat, G., & Ballester, P. J. (2022). Interpretable machine learning models to predict the resistance of breast cancer patients to doxorubicin from their microRNA profiles. Advanced Science (Weinheim an der Bergstrasse, Germany), 9(24), Article e2201501.","journal-title":"Advanced Science (Weinheim an der Bergstrasse, Germany)"},{"key":"10132_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061762","author":"HK Cha","year":"2022","unstructured":"Cha, H. K., Cheon, S., Kim, H., Lee, K. M., Ryu, H. S., & Han, D. (2022). Discovery of proteins responsible for resistance to three chemotherapy drugs in breast cancer cells using proteomics and bioinformatics analysis. Molecules. https:\/\/doi.org\/10.3390\/molecules27061762","journal-title":"Molecules"},{"issue":"11","key":"10132_CR146","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70572","volume":"29","author":"J Zhang","year":"2025","unstructured":"Zhang, J., & Sun, X. (2025). Multiomics-driven drug-cell interaction network for chemotherapy sensitivity prediction in metabolically defined triple-negative breast cancer subtypes. Journal of Cellular and Molecular Medicine, 29(11), Article e70572.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10132_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2024.101884","volume":"14","author":"MO Kadry","year":"2025","unstructured":"Kadry, M. O., Abd-Ellatef, G. E. F., Ammar, N. M., Hassan, H. A., Hussein, N. S., Kamel, N. N., et al. (2025). Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1\/EGFR\/PI3k\/PTEN crosstalk. Toxicology Reports, 14, Article 101884.","journal-title":"Toxicology Reports"},{"issue":"9","key":"10132_CR148","doi-asserted-by":"publisher","first-page":"e2415475122","DOI":"10.1073\/pnas.2415475122","volume":"122","author":"M Starostecka","year":"2025","unstructured":"Starostecka, M., Jeong, H., Hasenfeld, P., Benito-Garagorri, E., Christiansen, T., Stober Brasseur, C., et al. (2025). Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2\u2009+\u2009breast cancer organoid model. Proceedings of the National Academy of Sciences, 122(9), e2415475122.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10132_CR149","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s42003-022-03942-4","volume":"5","author":"CR Dufour","year":"2022","unstructured":"Dufour, C. R., Xia, H., B\u2019Chir, W., Perry, M. C., Kuzmanov, U., Gainullina, A., et al. (2022). Integrated multi-omics analysis of adverse cardiac remodeling and metabolic inflexibility upon ErbB2 and ERRalpha deficiency. Communications Biology, 5(1), 955.","journal-title":"Communications Biology"},{"issue":"2","key":"10132_CR150","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mol.119.115725","volume":"96","author":"N Wenningmann","year":"2019","unstructured":"Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019). Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Molecular Pharmacology, 96(2), 219\u2013232.","journal-title":"Molecular Pharmacology"},{"key":"10132_CR151","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07673-6","author":"Y Sun","year":"2025","unstructured":"Sun, Y., Xiao, L., Chen, L., & Wang, X. (2025). Doxorubicin-induced cardiac remodeling: Mechanisms and mitigation strategies. Cardiovascular Drugs and Therapy. https:\/\/doi.org\/10.1007\/s10557-025-07673-6","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"10132_CR152","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","volume":"129","author":"A Asnani","year":"2021","unstructured":"Asnani, A., Moslehi, J. J., Adhikari, B. B., Baik, A. H., Beyer, A. M., de Boer, R. A., et al. (2021). Preclinical models of cancer therapy-associated cardiovascular toxicity: A scientific statement from the American Heart Association. Circulation Research, 129(1), e21\u2013e34.","journal-title":"Circulation Research"},{"key":"10132_CR153","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale, R., Marzocco, S., & Popolo, A. (2024). Role of oxidative stress and inflammation in doxorubicin-induced cardiotoxicity: A brief account. International Journal of Molecular Sciences, 25, 13.","journal-title":"International Journal of Molecular Sciences"},{"key":"10132_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, Article 111708.","journal-title":"Biomedicine & Pharmacotherapy"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10132-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10132-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:43:21Z","timestamp":1782848601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10132-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":154,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10132"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10132-9","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"59"}}